The offering provides near-term cash but dilutes existing holders by ~8-10%. Monitor for use-of-proceeds details and pipeline milestones (Huntington's, epilepsy, Fabry) that could offset dilution. The stock may face near-term pressure from the overhang of additional shares and potential selling by arbitrageurs post-close.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 24 $48.85entry
- T+1 · 5mo ago +0.51%α +0.37% · $49.10
- T+5 · 5mo ago −7.53%α −9.24% · $45.17
- T+20 · 4mo ago −17.34%α −19.27% · $40.38
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, expecting approximately $225 million in gross proceeds. The offering includes a 30-day underwriter option for up to 741,758 additional shares. This dilutive capital raise provides cash runway for gene therapy pipeline programs (Huntington's, epilepsy, Fabry) but dilutes existing shareholders by roughly 10% based on the base offering.
Key Financial Metrics
Key Facts
- Priced 4,945,055 ordinary shares at $45.50 per share for ~$225M gross proceeds
- Underwriters have 30-day option to purchase up to 741,758 additional shares
- Offering expected to close on or about June 25, 2026
- Joint bookrunners: Leerink Partners, Stifel, Guggenheim Securities, RBC Capital Markets
- Lead manager: H.C. Wainwright & Co.
- Offered under automatically effective shelf registration statement on Form S-3 (File No. 333-284168)
Financial Impact
~$225M gross proceeds; dilution of ~10% from base offering (4.95M new shares vs. ~50M outstanding pre-offering, based on market cap of $2.8B and $45.50 price implying ~61.5M shares pre-offering, so ~8% dilution; plus up to 1.2% additional from over-allotment)
Risk Factors
- Dilution of ~8-10% from base offering; up to ~1.2% additional from over-allotment
- Potential near-term stock pressure from offering close and arbitrage selling
- Execution risk on pipeline programs; cash burn rate may require further financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3316560 |
Track record
38 reports on QURE
6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers